Logo image of LABS.CA

MEDIPHARM LABS CORP (LABS.CA) Stock Fundamental Analysis

TSX:LABS - Toronto Stock Exchange - CA58504D1006 - Common Stock - Currency: CAD

0.07  0 (0%)

Fundamental Rating

3

LABS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. While LABS seems to be doing ok healthwise, there are quite some concerns on its profitability. LABS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LABS has reported negative net income.
LABS had a negative operating cash flow in the past year.
LABS had negative earnings in each of the past 5 years.
LABS had a negative operating cash flow in each of the past 5 years.
LABS.CA Yearly Net Income VS EBIT VS OCF VS FCFLABS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

LABS has a worse Return On Assets (-14.35%) than 65.71% of its industry peers.
LABS has a Return On Equity (-17.28%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -14.35%
ROE -17.28%
ROIC N/A
ROA(3y)-28.72%
ROA(5y)-40.33%
ROE(3y)-34.34%
ROE(5y)-50.73%
ROIC(3y)N/A
ROIC(5y)N/A
LABS.CA Yearly ROA, ROE, ROICLABS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

LABS has a Gross Margin (30.31%) which is in line with its industry peers.
In the last couple of years the Gross Margin of LABS has declined.
The Profit Margin and Operating Margin are not available for LABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-3.36%
LABS.CA Yearly Profit, Operating, Gross MarginsLABS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

More info and screens

5

2. Health

2.1 Basic Checks

LABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LABS has been increased compared to 1 year ago.
The number of shares outstanding for LABS has been increased compared to 5 years ago.
Compared to 1 year ago, LABS has an improved debt to assets ratio.
LABS.CA Yearly Shares OutstandingLABS.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
LABS.CA Yearly Total Debt VS Total AssetsLABS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -1.47, we must say that LABS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.47, LABS is doing worse than 68.57% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that LABS is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.00, LABS belongs to the best of the industry, outperforming 88.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.47
ROIC/WACCN/A
WACC9.21%
LABS.CA Yearly LT Debt VS Equity VS FCFLABS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

LABS has a Current Ratio of 3.61. This indicates that LABS is financially healthy and has no problem in meeting its short term obligations.
LABS has a better Current ratio (3.61) than 91.43% of its industry peers.
A Quick Ratio of 2.41 indicates that LABS has no problem at all paying its short term obligations.
LABS's Quick ratio of 2.41 is amongst the best of the industry. LABS outperforms 85.71% of its industry peers.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 2.41
LABS.CA Yearly Current Assets VS Current LiabilitesLABS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

LABS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.50%, which is quite impressive.
LABS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.23%.
Measured over the past years, LABS shows a very negative growth in Revenue. The Revenue has been decreasing by -20.15% on average per year.
EPS 1Y (TTM)22.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
Revenue 1Y (TTM)16.23%
Revenue growth 3Y24.58%
Revenue growth 5Y-20.15%
Sales Q2Q%10.59%

3.2 Future

Based on estimates for the next years, LABS will show a very strong growth in Earnings Per Share. The EPS will grow by 41.42% on average per year.
Based on estimates for the next years, LABS will show a quite strong growth in Revenue. The Revenue will grow by 14.56% on average per year.
EPS Next Y74.5%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.35%
Revenue Next 2Y14.56%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LABS.CA Yearly Revenue VS EstimatesLABS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
LABS.CA Yearly EPS VS EstimatesLABS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 -0.1 -0.2 -0.3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LABS.CA Price Earnings VS Forward Price EarningsLABS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LABS.CA Per share dataLABS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 0.06 0.08 0.1

4.3 Compensation for Growth

A more expensive valuation may be justified as LABS's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

LABS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIPHARM LABS CORP

TSX:LABS (7/17/2025, 7:00:00 PM)

0.07

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-12 2025-08-12
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.71%
Ins Owner ChangeN/A
Market Cap29.06M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.41%
Min Revenue beat(2)0.49%
Max Revenue beat(2)8.33%
Revenue beat(4)2
Avg Revenue beat(4)-3.45%
Min Revenue beat(4)-21.53%
Max Revenue beat(4)8.33%
Revenue beat(8)4
Avg Revenue beat(8)-7.37%
Revenue beat(12)5
Avg Revenue beat(12)-4.06%
Revenue beat(16)5
Avg Revenue beat(16)-7.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.1
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.35%
ROE -17.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.31%
FCFM N/A
ROA(3y)-28.72%
ROA(5y)-40.33%
ROE(3y)-34.34%
ROE(5y)-50.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-3.36%
F-Score6
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.83%
Cap/Sales 0.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 2.41
Altman-Z -1.47
F-Score6
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)27.57%
Cap/Sales(3y)1.89%
Cap/Sales(5y)6.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
EPS Next Y74.5%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.23%
Revenue growth 3Y24.58%
Revenue growth 5Y-20.15%
Sales Q2Q%10.59%
Revenue Next Year13.35%
Revenue Next 2Y14.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y57.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.05%
OCF growth 3YN/A
OCF growth 5YN/A